Bernstein Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $11.9

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

Bernstein analyst Jeffrey Walch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underperform to Market Perform and raises the price target from $9.8 to $11.9.